¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"end product"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • end
    ³¡, Á¾¸», ¸»´Ü
  • end apparatus
    Á¾¸»ÀåÄ¡
  • end artery
    ³¡µ¿¸Æ
  • end group
    ¸»´Ü±â
  • end organ
    Á¾¸»±â°ü
  • end organ deafness
    Á¾¸»±â°ü³­Ã»
  • end-brush
    Ãà»è³¡°¡Áö
  • end-bud
    ²¿¸®½Ï
  • end-diastolic
    È®À帻±â
  • end-diastolic pressure
    È®Àå±â¸»¾Ð·Â
  • end-diastolic volume
    È®Àå±â¸»¿ëÀû
  • end-foot
    Á¾¸»´ÜÃß
  • end-pressure
    Á¾¾Ð, Á¾¸»¾Ð
  • end-systolic volume
    ¼öÃà±â¸»¿ëÀû
  • end-tidal
    È£ÈíÁ¾±â-
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acromial end
    ºÀ¿ì¸®³¡
  • apical end
    ²ÀÁö³¡
  • end apparatus
    Á¾¸»ÀåÄ¡
  • end artery
    ³¡µ¿¸Æ
  • end to side anastomosis
    ³¡¿·¿¬°á(¼ú), ´ÜÃø¿¬°á(¼ú)
  • Krause¡¯s end bulb
    Å©¶ó¿ìÁ¦³¡¸Á¿ï
  • double-end graft
    ¾ç³¡À̽Ä, ½Ö´ÜÀ̽Ä
  • end-organ deafness
    Á¾¸»±â°ü³­Ã»
  • free end saddle partial denture
    À¯¸®´Ü±¹ºÎÀÇÄ¡
  • end
    ³¡
  • end-brush
    Ãà»è³¡°¡Áö
  • end-bud
    ²¿¸®½Ï
  • end-foot
    (¢¡bouton terminal) Á¾¸»´ÜÃß
  • end-pressure
    Á¾¾Ð, Á¾¸»¾Ð
  • end group
    ¸»´Ü±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metabolic product
    ´ë»ç»ê¹°(¡­ß§Úª).
  • otoacoustic emission, distortion product
    ÀÌÀ½Çâ¹æ»ç¿Ö°î¹°
  • product costing
    Á¦Ç°°¡°Ý»êÁ¤
  • product of metabolism
    ´ë»ç»ê¹°(ÓÛÞóß§Úª).
  • skin care product
    ÇǺΰü¸®Á¦
  • split product
    ºÐ¸®»ê¹°.
  • substitution product
    ġȯü(öÇüµô÷).
  • tensile product
    ½ÅÀåÀû(ãßíåîÝ).
  • acromial end
    ºÀ¿ì¸®³¡
  • advanced glycosylation end products
    ÁøÇ༺´çÈ­Á¾¸»»ý¼º¹°(òäú¼àõÓÐûùðûØÇßæà÷Úª)
  • double-end graft
    ½Ö´ÜÀ̽Ä.
  • end apparatus
    Á¾¸»ÀåÄ¡(ðûØÇíûöÇ).
  • end artery
    Á¾µ¿¸Æ(ðûÔÑØæ).
  • end bulb of Krause
  • end dilution value =EDV
    ü¿ÜÈñ¼®Ä¡(ô÷èâýüà·ö·).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • end absorption
    ³¡ÆÄÀå(÷îíþ) Èí¼ö(ýåâ¥)
  • end carbon chain
    ³¡Åº¼Ò(÷©áÈ) »ç½½
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • end labeling
    Á¾´ÜÇ¥Áö (ðûÓ®øöò½)
  • end plate
    Á¾¸»ÆÇ(ðûØÇ÷ù)
  • end point
    Á¾¸»Á¡(ðûØÇïÇ)
  • end-point method
    Á¾¸»Á¡¹ý(ðûØÇïÇÛö)
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
  • fast-assembly end
    ?
  • frayed end
    Ç®¸° ³¡
  • minus end
    ¸¶À̳ʽº Á¾´Ü(ðýÓ¨)
  • plus end
    Ç÷¯½º Á¾´Ü(ðûÓ®)
  • reducing end
    ȯ¿ø¼º Á¾´Ü(ü½êªàõðûÓ®)
  • slow-assembly end
    ¿Ï¼Ó±¸Ãà ¸»´Ü(èÐáÜϰõéØÇÓ®)
  • sticky end
    Á¡Âø Á¾´Ü (ïÄó·ðûÓ®)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CEEA curved end-to-end anastomosis [stapler]
EDCS end-diastolic chamber stiffness; end-diastolic circumferential stress
EDL end-diastolic length; end-diastolic load; estimated date of labor; extensor digitorum longus
EEA electroencephalic audiometry; end-to-end anastomosis
ES ejection sound; elastic stocking; electrical stimulus, electrical stimulation; electroshock; emergen...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DPE Distortion Product Emission
DPOE Distortion product otoacoustic emissions
DPE Distortion-product otoacoustic emission
DAP Dose area product
ESP Excretory-secretory product
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central end
    Á᫐ ¸»´Ü
  • end apparatus
    Á¾¸» ÀåÄ¡
  • end feel
    Á¾¸»°¨, Á¾¸» °¨°¢
  • end path
    Á¾·Î
  • end-expiration
    È£Èí °áÇ٠ȣ±â ¸»±â
  • end-feel
    Á¾¸»°¨
    ¿ÏÀüÇÑ ´Éµ¿ °³±¸·ÎºÎÅÍ ¿ÏÀüÇÑ ¼öµ¿ °³±¸±îÁö °üÀýÀ» ¼ÕÀ¸·Î Á¶ÀÛÇÏ´Â µ¿¾È ´À²¸Áö´Â ÀúÇ×°¨.
  • end-organ
    Á¾¸» ±â°ü, ¸»´Ü±â, Á¾¸» ½Å°æ ¼Òü
    Áö°¢ ½Å°æÀÇ ÇÇÆ÷µÈ Ä¿´Ù¶õ Á¾¸»ºÎ.
  • free end saddle partial denture
    À¯¸®´Ü ±¹ºÎ ÀÇÄ¡
    ¾Ç±ÃÀÇ ÈĹ濡 ÀÜÁ¸Ä¡°¡ ÆíÃø ¶Ç´Â ¾çÃø¼ºÀ¸·Î ¾øÀ» ¶§ Á¦ÀÛµÈ ±¹¼Ò ÀÇÄ¡ÀÌ´Ù.
  • joint end-feel
    °üÀý Á¾¸»°¨
  • left ventricular end-diastolic volume
    Á ½É½Ç À̿ϱ⸻ ¿ëÀû
  • soft end feel
    ºÎµå·¯¿î Á¾¸»°¨
  • vibrating end
    Áøµ¿ ¸»´ÜºÎ
  • zero end expiratory pressure
    È£±â¸» ¹«¾Ð, È£±â¸» ¹«¿µ¾Ð
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
product surveillance, postmarketing Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
(12 Dec 1998)
secondary product <plant biology> End product of plant cell metabolism, which accumulates in or is secreted from, the cell. Includes anthocyanins, alkaloids, etc. Some are of major economic importance, for example as drugs. In contrast to a primary product that is involved in the vital metabolism of the plant.
(18 Nov 1997)
spallation product An atomic species produced in the course of the spallation of any atom.
(05 Mar 2000)
substitution product A product obtained by replacing one atom or group in a molecule with another atom or group.
(05 Mar 2000)
double product The product of systolic blood pressure multiplied by the heart frequency; a measure of heart work load.
See: Robinson index.
(05 Mar 2000)
trade name product <pharmacology> Trademarked proprietary preparations containing the generic substance. Some foreign trade name products have been selectively included here due to the relative popularity of the generic medication.
(17 Mar 1998)
fission product An atomic species produced in the course of the fission of a larger atom such as 235U.
(05 Mar 2000)
acromial end of clavicle The flattened lateral end of the clavicle that articulates with the acromion and is anchored to the coracoid process by the conoid and trapezoid ligaments.
Synonym: extremitas acromialis claviculae, acromial end of clavicle.
(05 Mar 2000)
blunt-end Refers to double-stranded DNA in which there are no unpaired bases at the end.
(05 Mar 2000)
blunt-end DNA <molecular biology> A fragment of a DNA molecule in which the ends of both strands are even with each other rather than one strand being longer than the other.
(09 Oct 1997)
blunt-end ligation A lab technique to join together two pieces of blunt-end DNA, such as an insert into a cloning vector, which requires the enzyme ligase because there are no single-stranded overhanging ends for the attachment to form more spontaneously, by itself.
(09 Oct 1997)
by-end Private end or interest; secret purpose; selfish advantage.
Alternative forms: bye-end.
(20 Mar 1998)
capped 5'-end A methylated (has a -CH3 attached) guanosine nucleotide attached to the 5'-end (the beginning) of an eukaryotic mRNA, thought to give the mRNA stability.
(09 Oct 1997)
glycosylation end products, advanced Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus.
(12 Dec 1998)
root end cyst An inflammatory odontogenic cyst derived histogenetically from Malassez' epithelial rests surrounding the root apex of a nonvital tooth.
Synonym: periapical cyst, radicular cyst, root end cyst.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • product liability
    (ºÒ·® »óǰ¿¡ ´ëÇØ ¼ÒºñÀÚ¿¡°Ô Áö´Â) »ý»ê¹°(ÀÚ) Ã¥ÀÓ
  • product life cycle
    Á¦Ç°ÀÇ ¶óÀÌÇÁ »çÀÌŬ
  • product line
    (¸¶ÄÉÆÃ)Á¦Ç° ¶óÀÎ(°°Àº ±â´ÉÀ» °¡Áø ¼­·Î °ü·Ã ±íÀº Á¦Ç°±º)
  • product mix
    (¸¶ÄÉÆÃ)Á¦Ç° ¹Í½º(ÆÇ¸ÅµÇ´Â ÀüÁ¦Ç°ÀÇ ¸®½ºÆ®,Æø°ú ±íÀÌÀÇ µÎÂ÷¿ø)
  • residual product
    ÀÜ¿© »ý»ê¹°;ºÎ»ê¹°
  • staple product
    ÁÖ¿ä »ê¹°
  • by-end
    À̱âÀûÀÎ µ¿±â
  • end
    ³¡,¸ñÀû,°á¸»
  • to the end
    ³¡±îÁö
  • END
    European Nuclear Disarmament
  • East End
    ·±´ø µ¿Á· ³¡(ÀÌÀüÀÇ ºó¹Î°¡)
  • Land's End
    ¿µ±¹ Cornwall ÁÖ ¼­´ÜÀÇ ²É
  • book end
    ºÏ¿£µå(Ã¥²ÉÀÌÀÇ ÀÏÁ¾)
  • butt end
    ±½ÀºÂÊÀdz¡;±×·çÅͱâ;³²Àº ºÎºÐ(Á¶°¢)
  • closed-end
    (ÅõÀÚ ½ÅŹÀÌ)ÀÚº»¾× °íÁ¤ÀÎ;Æó¼â½ÄÀÎ;(´ãº¸°¡)´ëºÎ ±Ý¾×À» °íÁ¤½ÃŲ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á